Business as Usual for Stratagene Customers As Company Starts Integrating into Agilent | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
One week after Agilent Technologies completed its $250 million acquisition of Stratagene, a company official said that he expects Stratagene’s molecular diagnostic collaborations to remain on track and that Agilent will be in close contact with those partners.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.